These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30400732)

  • 1. Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio.
    Yoo JJ; Cho EJ; Lee B; Kim SG; Kim YS; Lee YB; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Gut Liver; 2018 Nov; 12(6):714-721. PubMed ID: 30400732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
    Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
    Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort.
    Lin L; Piao M; Jiang X; Lv H; Zhao N; Yang F; Sun C
    BMJ Open; 2017 Jul; 7(7):e015304. PubMed ID: 28706093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population.
    Alomari M; Covut F; Al Momani L; Chadalavada P; Hitawala A; Young MF; Romero-Marrero C
    JGH Open; 2020 Apr; 4(2):132-139. PubMed ID: 32280755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation.
    Lin BY; Zhou L; Geng L; Zheng ZY; Jia JJ; Zhang J; Yao J; Zheng SS
    World J Gastroenterol; 2015 Mar; 21(11):3317-24. PubMed ID: 25805939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid.
    Cheung KS; Seto WK; Fung J; Lai CL; Yuen MF
    Clin Transl Gastroenterol; 2017 Jun; 8(6):e100. PubMed ID: 28640288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
    Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
    Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score.
    Chan AW; Chan RC; Wong GL; Wong VW; Choi PC; Chan HL; To KF
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1391-6. PubMed ID: 25753927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary biliary cirrhosis: Dutch application of the Mayo Model before and after orthotopic liver transplantation.
    van Dam GM; Verbaan BW; Therneau TM; Dickson ER; Malinchoc M; Murtaugh PA; Huizenga JR; Gips CH
    Hepatogastroenterology; 1997; 44(15):732-43. PubMed ID: 9222682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A brief review on prognostic models of primary biliary cholangitis.
    Chen S; Duan W; You H; Jia J
    Hepatol Int; 2017 Sep; 11(5):412-418. PubMed ID: 28913620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis.
    Yang Z; Liang Y; Lin F; Zhang Z; Luo W; Zhang Y; Zhong R
    Int Immunopharmacol; 2018 Mar; 56():285-290. PubMed ID: 29414663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients.
    Marenco-Flores A; Rojas Amaris N; Kahan T; Sierra L; Barba Bernal R; Medina-Morales E; Goyes D; Patwardhan V; Bonder A
    J Clin Med; 2024 Aug; 13(15):. PubMed ID: 39124763
    [No Abstract]   [Full Text] [Related]  

  • 20. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.